lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-30. Numbers and descriptions here follow the published literature rather than marketing material.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
CD49b receptor is located on Natural killer cells, Natural killer T cells, and certain types of activated T cell. It mediates migration and cell-to-cell interactions within tissue microenvironments. As for the use of the receptor in immunology, the co-expression of the CD49b receptor with the lymphocyte activation gene 3 receptor (LAG-3) is widely used in studies as a phenotypic marker of Tr1 regulatory T cell, which is a particular type of regulatory T cell responsible for maintaining immune tolerance. Not only in physiological conditions, but also in the case of pathologies, the integrin α2β1 participates in tissue remodeling and turnover of extracellular matrix. The pathway of collagen signal transduction through the integrin α2β1 controls collagen production and other aspects of matrix organization. The pathology in case of disorders of this process may be observed in fibrosis, whereas dysregulation of α2β1 integrin expression is linked to metastasis and tumor invasion. It may be concluded that integrin α2β1 is a functional molecule, and not only a molecular structure for adhesion.
Born on April 19, 1970, in Tatsuno, Ueda graduated from the Osaka University of Arts in 1993. In 1995, after trying to make a living as a visual artist, Ueda decided to pursue a career in the video game industry. He joined the developer Warp and worked as an animator on the game Enemy Zero for the Sega Saturn under the director Kenji Eno. He described his time there as "arduous", as the game was behind schedule and everyone on the project had to work more than normal to meet the release deadline. Eno, who also owned the company, did not think he was that great a digital artist, but handpicked Ueda because of his talent with concepts and design. Ueda worked at WARP for a year and a half.
==== Correspondence to clinical effects ==== Ziprasidone mostly affects the receptors of dopamine (D2), serotonin (5-HT2A, partially 5-HT1A, 5-HT2C, and 5-HT1D) and epinephrine/norepinephrine (α1) to a high degree, while of histamine (H1) - moderately. It also somewhat inhibits reuptake of serotonin and norepinephrine, though not dopamine. Ziprasidone's efficacy in treating the positive symptoms of schizophrenia is believed to be mediated primarily via antagonism of the dopamine receptors, specifically D2. Blockade of the 5-HT2A receptor may also play a role in its effectiveness against positive symptoms, though the significance of this property in antipsychotic drugs is still debated among researchers. Blockade of 5-HT2A and 5-HT2C and activation of 5-HT1A as well as inhibition of the reuptake of serotonin and norepinephrine may all contribute to its ability to alleviate negative symptoms.; however, its effects on the 5-HT1A receptor may be limited as a study found ziprasidone would likely "produce detectable occupancy [of 5-HT1A receptors] only at higher doses that would produce unacceptable levels of side effects in man, although lower doses are sufficient to produce pharmacological effects." The relatively weak antagonistic actions of ziprasidone on the α1-adrenergic receptor likely in part explains some of its side effects, such as orthostatic hypotension. Unlike many other antipsychotics, ziprasidone has no significant affinity for the mACh receptors, and as such lacks any anticholinergic side effects.
Liu Wenhui (simplified Chinese: 刘文辉; traditional Chinese: 劉文輝; pinyin: Liú Wénhuī; Wade–Giles: Liu Wen-hui; 10 January 1895 – 24 June 1976) was a Chinese general and warlord of Sichuan and Xikang provinces (Sichuan clique). At the beginning of his career, he was aligned with the Kuomintang (KMT), commanding the Sichuan-Xikang Defence Force from 1927 to 1929. In 1929, he became Sichuan governor before being ousted by a coalition of warlords in 1933; from there, he controlled the western part of Sichuan province, then known as Xikang, ruling the area as a personal fiefdom. He maintained his autonomy from the Nationalist government and pursued development programs in the province, which he funded through the trade of opium and by maintaining cordial relations with Chiang Kai-shek during the Second Sino-Japanese War. In 1949 he defected to the Communist forces of Mao Zedong, and went on to hold high office in the new People's Republic of China, serving as Minister of Forestry (1959–1967), member of the National People's Congress, member of the National Committee of the Chinese People's Political Consultative Conference, and member of the Central Committee of the Revolutionary Committee of the Chinese Kuomintang.
=== Master protocol === A master protocol includes multiple substudies, which may have different objectives and involve coordinated efforts to evaluate one or more medical products in one or more diseases or conditions within the overall study structure. Trials that could develop a master protocol include the umbrella trial (multiple medical products for a single disease), platform trial (multiple products for a single disease entering and leaving the platform), and basket trial (one medical product for multiple diseases or disease subtypes). Genetic testing enables researchers to group patients according to their genetic profile, deliver drugs based on that profile to that group and compare the results. Multiple companies can participate, each bringing a different drug. The first such approach targets squamous cell cancer, which includes varying genetic disruptions from patient to patient. Amgen, AstraZeneca and Pfizer are involved, the first time they have worked together in a late-stage trial. Patients whose genomic profiles do not match any of the trial drugs receive a drug designed to stimulate the immune system to attack cancer.
Sources: en.wikipedia.org
== Medical uses == Racecadotril is used for the treatment of acute diarrhea in children and adults and has better tolerability than loperamide, as it causes less constipation and flatulence. Several guidelines have recommended racecadotril use in addition to oral rehydration treatment in children with acute diarrhea.
Mepitiostane, sold under the brand name Thioderon, is an orally active antiestrogen and anabolic–androgenic steroid (AAS) of the dihydrotestosterone (DHT) group which is marketed in Japan as an antineoplastic agent for the treatment of breast cancer. It is a prodrug of epitiostanol. The drug was patented and described in 1968.
Avoiding smoking Cutting down on fats to help reduce the amount of plaque buildup Eating a healthy diet, including plenty of fruits and vegetables Limiting sodium in the diet, thereby reducing blood pressure Exercising regularly Moderating intake of alcohol, stimulants, sympathomimetics, etc. Maintaining a healthy weight In addition, it is important to control any underlying medical conditions that may increase the risk of stroke or TIA, including:
organometallic chemistry, compounds with metal-carbon bonds. This area touches on organic synthesis, which employs many organometallic catalysts and reagents. cluster chemistry, compounds with several metals bound together with metal–metal bonds or bridging ligands. bioinorganic chemistry, biomolecules that contain metals. This area touches on medicinal chemistry. materials chemistry and solid state chemistry, extended (i.e. polymeric) solids exhibiting properties not seen for simple molecules. Many practical themes are associated with these areas, including ceramics.
Sources: en.wikipedia.org
an aromatic oxo acid + L-glutamate The two substrates of this enzyme are an aromatic amino acid and α-ketoglutaric acid. Its products are the corresponding α-keto acid and L-glutamic acid. For example, the enzyme characterised from Escherichia coli interconverts phenylalanine and phenylpyruvic acid:
In March 2025, Cerebras announced plans to construct six new datacenters in Dallas, Minneapolis, Oklahoma City, Montreal, New York, and France, increasing inference capacity twentyfold to over 40 million tokens per second, expecting increased demand from Llama 4 and DeepSeek. Meta Platforms agreed to use Cerebras products to power the Llama API in April 2025. In April 2025, Cerebras and Ranovus announced a contract from DARPA. In May 2025, Cerebras beat NVIDIA's Blackwell in Llama 4 Inference with more than 2,500 tokens per second/user, compared to 1,000 for Blackwell, on the 400B-parameter Llama 4 Maverick model in testing by an independent benchmarking firm. In July 2025, Cerebras unveiled Qwen3-235B, an ultra-fast deployment of Alibaba Group's open-weight Qwen AI models, with full 131k context support on its inference cloud platform. In January 2026, Cerebras signed a deal with OpenAI to deliver 750 megawatts of computing power through 2028 for $10 billion. As part of the agreement with OpenAI, the company is temporarily prohibited from selling its products to Anthropic. In March 2026, Amazon Web Services agreed to purchase CS-3 systems to be used for its Trainium-powered servers set to be deployed on Amazon Bedrock in its data centers. In August 2026, CS-4 system was introduced.
=== Sarcopenia === Sarcopenia is the degenerative loss of skeletal muscle mass, quality, and strength associated with aging. This involves muscle atrophy, reduction in number of muscle fibers and a shift towards "slow twitch" or type I skeletal muscle fibers over "fast twitch" or type II fibers. The rate of muscle loss is dependent on exercise level, co-morbidities, nutrition and other factors. There are many proposed mechanisms of sarcopenia, such as a decreased capacity for oxidative phosphorylation, cellular senescence or an altered signaling of pathways regulating protein synthesis, and is considered to be the result of changes in muscle synthesis signalling pathways and gradual failure in the satellite cells which help to regenerate skeletal muscle fibers, specifically in "fast twitch" myofibers. Sarcopenia can lead to reduction in functional status and cause significant disability but is a distinct condition from cachexia although they may co-exist. In 2016 an ICD code for sarcopenia was released, contributing to its acceptance as a disease entity.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.